Philips and artificial intelligence (AI) provider Quibim are collaborating to improve prostate cancer care using AI-enabled MRI and image analysis software, aiming to enhance speed, accuracy, and cost-effectiveness in diagnosis and treatment.

Prostate cancer is a global health concern, affecting millions of men worldwide. Early detection plays a crucial role in improving patient outcomes. Currently, the primary method for early detection is the prostate-specific antigen (PSA) blood test, which can result in false positives and unnecessary biopsies. Philips and Quibim’s solution is looking to address these challenges.

MR exams have shown promise as a triaging tool to guide biopsy decisions and provide valuable diagnostic insights independently of PSA testing. While MR exams are generally more expensive and time-consuming than PSA tests, they have the potential to reduce the number of unnecessary biopsies and offer better-targeted therapy for prostate cancer patients, resulting in overall cost savings and faster, more accurate diagnoses.

Philips and Quibim are collaborating to create an integrated solution that automates real-time prostate gland segmentation in MR images using Quibim’s QP-Prostate software and Philips’ AI-based MR imaging techniques, empowering clinicians with speed and precision to meet the rising demand for MR exams, resulting in improved diagnostic confidence, personalized treatment, and better patient outcomes.

Ruud Zwerink, general manager of MR at Philips, states, “This collaboration with Quibim is the latest example of our commitment to build an AI ecosystem into our Diagnostic Imaging portfolio to help detect conditions like cancer earlier, improve the rate of accurate first-time-right diagnosis, and streamline hospital operations to provide better care at lower costs.”

Quibim CEO Angel Alberich-Bayarri also spoke out about partnership, commenting: “This integrated approach, combined with workflow-enhancing features, is aimed at mitigating staff shortages, high burn-out rates, and cost constraints currently being experienced by many radiology and oncology departments. Patients will also greatly benefit from far less complex and painful biopsy procedures and more personalized treatment.”